Federica Guffanti

Dr. Federica Guffanti

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2014 in Cancer Research
Verified
Journal Article
Closed access
PDF file
Francesca RicciFrancesca Ricci
Francesca Ricci
FBFrancesca Bizzaro
Francesca Bizzaro
MCMarta Cesca
Marta Cesca
FGFederica Guffanti
Federica Guffanti
MGMonica Ganzinelli
Monica Ganzinelli
RGRaffaella Giavazzi
Raffaella Giavazzi
Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy. On the basis of its histopathology and molecular-genomic changes, ovarian cancer has been divided into subtypes, each with distinct biology and outcome. The aim of this study was to develop a panel of patient-derived EOC xenografts that recapitulate the molecular and biologic heterogeneity of human ovarian cancer. Thirty-four EOC xenografts were successfully established, either subcutaneously or intraperitoneally, in nude mice. The xenografts were histologically similar to the corresponding patient tumor and comprised all the major ovarian cancer subtypes. After orthotopic transplantation in the bursa of the mouse ovary, they disseminate into the organs of the peritoneal cavity and produce ascites, typical of ovarian cancer. Gene expression analysis and mutation status indicated a high degree of similarity with the original patient and discriminate different subsets of xenografts. They were very responsive, responsive, and resistant to cisplatin, resembling the clinical situation in ovarian cancer. This panel of patient-derived EOC xenografts that recapitulate the recently type I and type II classification serves to study the biology of ovarian cancer, identify tumor-specific molecular markers, and develop novel treatment modalities. Cancer Res; 74(23); 6980–90. ©2014 AACR.

1 March 2020 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
ECElisa Caiola
Elisa Caiola
AIAlice Iezzi
Alice Iezzi
MTMichele Tomanelli
Michele Tomanelli
EBElisa Bonaldi
Elisa Bonaldi
ASArianna Scagliotti
Arianna Scagliotti
Mirko MarabeseMirko Marabese
Mirko Marabese

25 October 2014 in Oncotarget
Verified
Journal Article
Open access
PDF file
RCRosaria Chilà
Rosaria Chilà
ABAlessandra Basana
Alessandra Basana
MLMonica Lupi
Monica Lupi
FGFederica Guffanti
Federica Guffanti
EGEugenio Gaudio
Eugenio Gaudio
LCLaura Carrassa
Laura Carrassa
Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma

1 November 2016 in Cancer Treatment Reviews
Verified
Journal Article
Closed access
RCRosaria Chilà
Rosaria Chilà
FGFederica Guffanti
Federica Guffanti
Giovanna DamiaGiovanna Damia
Giovanna Damia

1 January 2017 in Neoplasia
Verified
Journal Article
Open access
FGFederica Guffanti
Federica Guffanti
RCRosaria Chilà
Rosaria Chilà
EBEzia Bello
Ezia Bello
MZMassimo Zucchetti
Massimo Zucchetti
MZMonique Zangarini
Monique Zangarini
Giovanna DamiaGiovanna Damia
Giovanna Damia
The fibroblast growth factor receptor (FGFR) pathway has been implicated both as an escape mechanism from anti-angiogenic therapy and as a driver oncogene in different tumor types. Lucitanib is a small molecule inhibitor of vascular endothelial growth factor (VEGF) receptors 1 to 3 (VEGFR1 to 3), platelet derived growth factor α/β (PDGFRα/β) and FGFR1-3 tyrosine kinases and has demonstrated activity in a phase I/II clinical study, with objective RECIST responses in breast cancer patients with FGFR1 or FGF3/4/19 gene amplification, as well as in patients anticipated to benefit from anti-angiogenic agents. We report here the in vitro and in vivo antitumor activity of lucitanib in experimental models with or without FGFR1/2 amplification or mutations. In cell assays, lucitanib potently inhibited the growth of tumor cell lines with amplified FGFR1 or mutated/amplified FGFR2. In all xenograft models studied, lucitanib demonstrated marked tumor growth inhibition due to potent inhibition of angiogenesis. Notably, in two lung cancer models with FGFR1 amplification, the antitumor efficacy was higher, suggesting that the simultaneous inhibition of VEGF and FGF receptors in FGFR1 dependent tumors can be therapeutically advantageous. Similar antitumor activity was observed in FGFR2 wild-type and amplified or mutated xenograft models. Pharmacokinetic studies showed lucitanib plasma concentrations in the micro/sub-micromolar range demonstrated drug accumulation following repeated lucitanib administration.

1 April 2022 in Cancers
Verified
Journal Article
Open access
PDF file
MCMichela Chiappa
Michela Chiappa
FGFederica Guffanti
Federica Guffanti
MAMartina Anselmi
Martina Anselmi
MLMonica Lupi
Monica Lupi
NPNicolò Panini
Nicolò Panini
Giovanna DamiaGiovanna Damia
Giovanna Damia
Background. Poly(ADP-ribose) polymerases inhibitor (PARPi) have shown clinical efficacy in ovarian carcinoma, especially in those harboring defects in homologous recombination (HR) repair, including BRCA1 and BRCA2 mutated tumors. There is increasing evidence however that PARPi resistance is common and develops through multiple mechanisms. Methods. ID8 F3 (HR proficient) and ID8 Brca1-/- (HR deficient) murine ovarian cells resistant to olaparib, a PARPi, were generated through stepwise drug concentrations in vitro. Both sensitive and resistant cells lines were pharmacologically characterized and the molecular mechanisms underlying olaparib resistance. Results. In ID8, cells with a HR proficient background, olaparib resistance was mainly caused by overexpression of multidrug resistance 1 gene (MDR1), while multiple heterogeneous co-existing mechanisms were found in ID8 Brca1-/- HR-deficient cells resistant to olaparib, including overexpression of MDR1, a decrease in PARP1 protein level and partial reactivation of HR repair. Importantly, combinations of ATR, Chk1 and Wee1 inhibitors with olaparib were synergistic in sensitive and resistant sublines, regardless of the HR cell status. Conclusion. Olaparib-resistant cell lines were generated and displayed multiple mechanisms of resistance, which will be instrumental in selecting new possible therapeutic options for PARPi-resistant ovarian tumors.